Novel pharmaceutical methods, combinations and compositions for reducing gastric bleeding during aspirin therapy for inflammation are disclosed. Compounds used in combination with aspirin are phenoxy- and substituted-phenoxy alcohols, carbamates, aminoalcohols, carbamoylalcohols, oxazolidinones, pyrrolidines, thiosemicarbazides and aminoalkylacetamides. The compounds act systemically to ameliorate gastric bleeding otherwise caused by aspirin.

Novel pharmaceutical methods, combinations and compositions for reducing gastric bleeding during aspirin therapy for inflammation are disclosed. Compounds used in combination with aspirin are phenylalkylamines and phenylalkylureas having the formula: ##STR1## wherein Z is selected from the group consisting of --NHR.sup.2 or ##STR2## and R is selected from the group consisting of hydrogen, halogen, lower-alkoxy and trifluoromethyl and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected from the gr...

An analogesic tablet containing aspirin, acetaminophen and caffeine of improved dissolution rate containing low-substituted hydroxypropylcellulose.

A formulation which allows administration of aspirin and like drugs and avoids gastrointestinal damage to a significant extent is described. A preferred formulation particularly useful for protecting the gastric mucosal lining of arthritic sufferers on a prolonged aspirin medication program comprises aspirin, glucose and sodium acetate or sodium citrate. A like composition containing dibromoaspirin in lieu of aspirin is helpful in reducing gastrointestinal damage to persons suffering from sickle...

A nonsteroidal anti-inflammatory drug composition containing as protectants against gastrointestinal injury, H.sub.1 blockers, H.sub.2 blockers, beta-adrenergic agonists, or combinations thereof, and an alkalizing agent and a process for administering such compositions.

Methods and compositions are provided for reducing the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The methods comprise administering a combination of: a cholesterol-lowering agent, such as an HMG CoA reductase inhibitor; an inhibitor of the renin-angiotensin system, such as an ACE inhibitor; aspirin; and optionally one or more of vitamin B.sub.6, vitamin B.sub.12, and folic acid. Pharmaceutica...

There is described a pharmaceutical mixture comprising 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, and aspirin or indomethacin. The mixture causes less gastrointestinal adverse effects than aspirin or indomethacin on their own.

An orally administrable pharmaceutical formulation is provided that combines, as active agents, a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, aspirin, and optionally at least one of vitamin B.sub.6, B.sub.12, and folate; the active agents are each present in a unit dose appropriate for once-daily dosing, and at least one of the active agents is contained in a dosage unit within the dosage form that physically separates it from the other active agents. The formulatio...

Disclosed is the method of reducing the incidence and severity of atherosclerosis, atherosclerotic central nervous system disease, claudication, coronary artery disease, homocystine related disorders, hypertension, peripheral vascular disease, presenile dementia and/or restenosis in humans by daily administration of an effective amount of a combination of acetylsalicylic acid (ASA), at least one antioxidant, a cyanocobalamin compound (Vitamin B12), a folic acid compound, a pyridoxine compound (V...

Disclosed is the method of reducing the incidence and severity of stroke, primary heart attack, and any subsequent heart attack or stroke in humans by daily administration of an effective amount of a combination of acetylsalicylic acid (ASA),a cyanocobalamin compound (Vitamin B12), a folic acid compound, and a pyridoxine compound (Vitamin B6) in an easy to take daily administration pack.